-
21.发明公开Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfall 审中-公开Nicht-neurotoxische纤溶酶原Aktivierende Faktoren zur Behandlung von Schlaganfall
公开(公告)号：EP2368567A1
公开(公告)日：2011-09-28
申请号：EP10011603.7
申请日：2002-10-31
CPC分类号： C12N9/6459 , A61K31/7068 , A61K38/49 , A61K45/06 , C12Y304/21068 , C12Y304/21069
摘要： Die Erfindung betrifft die Verwendung und Herstellung von nicht-neurotoxischen Plasminogen Aktivierenden Faktoren, beispielsweise aus Desmodus rotundus (DSPA), zur therapeutischen Behandlung des Schlaganfalls bei Menschen zur Bereitstellung eines neuen therapeutischen Ansatzes zur Behandlung des Schlaganfalls beim Menschen.
摘要翻译： 使用纤溶酶原激活因子（A）治疗中风，其中（A）的活性在纤维蛋白存在下增加超过650倍是新的。 还包括以下独立权利要求：（1）具有包含His420，Asn421，Ala422和Cys423的自溶回路的组织纤溶酶原激活物（tPA）; （2）尿激酶具有包含Val420，Thr421，Asp422和Ser423的自溶回路; 和（3）含有（A）和至少一种其它医药活性剂或其盐的药物组合物。 活性：保护脑。 没有给出生物数据。 行动机制：无给予。
-
22.发明公开
公开(公告)号：EP1997510A8
公开(公告)日：2011-04-13
申请号：EP08012976.0
申请日：2002-10-31
CPC分类号： C12N9/6459 , A61K31/7068 , A61K38/49 , A61K45/06 , C12Y304/21068 , C12Y304/21069
摘要： Die Erfindung betrifft die Verwendung und Herstellung von nicht-neurotoxischen Plasminogen Aktivierenden Faktoren, beispielsweise aus Desmo dus rotundus (DSPA), zur therapeutischen Behandlung des Schlaganfalls bei Menschen zur Bereitstellung eines neuen therapeutischen Ansatzes zur Behandlung des Schlaganfalls beim Menschen.
-
23.发明公开THROMBOMODULIN FOR INCREASING REPERFUSION AND PREVENTING BLOOD VESSELS OBSTRUCTION 审中-公开血栓调节加强再灌注防止血液血管梗阻
公开(公告)号：EP2175872A2
公开(公告)日：2010-04-21
申请号：EP08784685.3
申请日：2008-07-10
CPC分类号： A61K38/366
摘要： Use of thrombomodulin for the manufacture of a medicament for stimulating the reperfusion of an ischemic tissue or organ within a patient in the need thereof, in particular a stroke patient.
-
公开(公告)号：EP1622640A1
公开(公告)日：2006-02-08
申请号：EP04731137.8
申请日：2004-05-05
发明人： SÖHNGEN, Wolfgang
CPC分类号： A61K38/57 , A61K2300/00
摘要： The invention relates to the use of an inhibiting agent of t-PA of mediated activation of the glutamate receptor, preferably of the NMDA type, as neuroprotectives.
-
公开(公告)号：EP2999715A2
公开(公告)日：2016-03-30
申请号：EP14731163.3
申请日：2014-05-21
申请人： PAION Deutschland GmbH , Inserm
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/286 , C07K2317/34 , C07K2317/565
摘要： The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
-
26.发明公开Novel antibody useful in neurological or neurodegenerative disorders 审中-公开Eröper per ind ind ind ind ind ind ind ind ind ind ind ind ind ind ind ind ind
公开(公告)号：EP2805972A1
公开(公告)日：2014-11-26
申请号：EP13002850.9
申请日：2013-06-03
申请人： PAION Deutschland GmbH , Inserm
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/286 , C07K2317/34 , C07K2317/565
摘要： The present invention relates to an anti-NMDA antibody or fragment or derivative thereof which is effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D-aspartate (NMDA) receptors and to medical uses, in particular for the treatment of neurological or neurodegenerative disorders, e.g. multiple sclerosis.
摘要翻译： 本发明涉及有效抑制由N-甲基-D-天冬氨酸（NMDA）受体介导的组织型纤溶酶原激活剂（t-PA）和医学上的有害作用的抗NMDA抗体或其片段或衍生物 尤其用于治疗神经或神经变性疾病，例如， 多发性硬化。
-
公开(公告)号：EP2473185A1
公开(公告)日：2012-07-11
申请号：EP10706138.4
申请日：2010-01-29
申请人： PAION Deutschland GmbH , Inserm
IPC分类号： A61K38/49 , A61K39/395 , C07K14/705 , A61P25/00
CPC分类号： A61K38/49 , A61K2039/505 , C07K14/705 , C07K16/286 , C07K2317/76
摘要： The Invention relates to a protein or peptide consisting of a kringle portein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N- terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody.
-
28.发明公开Treatment of neurological or neurodegenerative disorders 审中-公开Behandlung von neurologischen und neurodegenerativen Erkrankungen
公开(公告)号：EP2289542A1
公开(公告)日：2011-03-02
申请号：EP09011149.3
申请日：2009-08-31
申请人： PAION Deutschland GmbH , Inserm
IPC分类号： A61K38/49 , A61K39/395 , C07K14/705 , A61P25/00
CPC分类号： A61K38/49 , A61K2039/505 , C07K14/705 , C07K16/286 , C07K2317/76
摘要： The Invention relates to a protein or peptide consisting of a kringle portein or peptide and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates also to an isolated antibody of fragment thereof which binds to the N-terminal domain of the NMDA receptor subunit NR1 (anti-NR1 antibody), whereas binding of the antibody or the fragment thereof prevents the cleavage of the extracellular domain of the NR1 subunit, or the fragment and its use for the treatment of neurological or neurodegenerative disorders, in particular stroke. The invention relates further to a pharmaceutical composition containing said kringle protein or peptide or anti-NR1 antibody.
摘要翻译： 本发明涉及由三环蛋白或肽组成的蛋白质或肽及其用于治疗神经或神经变性疾病，特别是中风的用途。 本发明还涉及其与NMDA受体亚单位NR1（抗NR1抗体）的N末端结构域结合的其分离的片段抗体，而抗体或其片段的结合阻止了细胞外结构域的切割 NR1亚基，或其片段及其用于治疗神经系统或神经退行性疾病，特别是中风的用途。 本发明还涉及含有所述三环蛋白或肽或抗NR1抗体的药物组合物。
-
29.发明授权NICHT-NEUROTOXISCHE PLASMINOGEN AKTIVIERENDE FAKTOREN ZUR BEHANDLUNG VON SCHLAGANFALL 有权无毒的NEURO纤溶酶原活化因子用于治疗中风
公开(公告)号：EP1441757B1
公开(公告)日：2008-07-23
申请号：EP02785348.0
申请日：2002-10-31
CPC分类号： C12N9/6459 , A61K31/7068 , A61K38/49 , A61K45/06 , C12Y304/21068 , C12Y304/21069
摘要： The invention concerns the use and the production of non-neurotoxic plasminogen activating factors, derived for example from the common vampire Desmodus rotundus (DSPA), for therapeutic treatment of stroke in humans. The invention provides a novel therapeutic base for treating stroke in humans.
-
公开(公告)号：EP1449849A3
公开(公告)日：2006-01-25
申请号：EP04009293.4
申请日：1993-02-05
发明人： Light, David Richard , Andrews, William H. , Clarke, Jeffrey Homer , Wydro, Robert Michael , Young, Patricia Ann
IPC分类号： C07K14/745 , C12N15/12 , A61K38/36
CPC分类号： C07K14/7455 , A61K38/00
摘要： The present invention relates to the single-chain thrombomodulin ("TM") and analogs thereof that are not susceptible to cleavage by proteases and retain the biological activity of thrombomodulin, as well as methods of use in, for example, antithrombotic therapy. Novel proteins, nucleic acid gene sequences, pharmaceuticals and methods of inhibiting thrombotic activity are disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.016 秒)
